Company news

Cue Biopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights

May 18, 2020

Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University

May 13, 2020

Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer

April 19, 2020

Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

March 16, 2020

Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies

January 20, 2020

Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights

November 11, 2019

Cue Biopharma to Present at Upcoming Investor Conferences in November 2019

November 5, 2019

Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

October 29, 2019

Cue Biopharma Announces Changes to its Board of Directors

October 8, 2019

Cue Biopharma Promotes Dr. Anish Suri to President and CSO

October 6, 2019

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma

September 29, 2019

← Newer news releases

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.